{"nctId":"NCT02551159","briefTitle":"Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer","startDateStruct":{"date":"2015-10-15","type":"ACTUAL"},"conditions":["Squamous Cell Carcinoma of the Head and Neck"],"count":823,"armGroups":[{"label":"Monotherapy","type":"EXPERIMENTAL","interventionNames":["Biological: MEDI4736"]},{"label":"Combination Therapy","type":"EXPERIMENTAL","interventionNames":["Biological: Tremelimumab","Biological: MEDI4736+Tremelimumab"]},{"label":"Standard of Care","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Cetuximab","Drug: 5-fluorouracil (5FU)","Drug: Cisplatin","Drug: Carboplatin"]}],"interventions":[{"name":"MEDI4736","otherNames":[]},{"name":"Tremelimumab","otherNames":[]},{"name":"MEDI4736+Tremelimumab","otherNames":[]},{"name":"Cetuximab","otherNames":[]},{"name":"5-fluorouracil (5FU)","otherNames":[]},{"name":"Cisplatin","otherNames":[]},{"name":"Carboplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥18 years at the time of screening\n2. Documented evidence of recurrent or metastatic SCCHN (oral cavity, oropharynx, hypopharynx, or larynx).\n3. A fresh tumor biopsy for the purpose of screening or an available archival tumor sample. Tumor lesions used for fresh biopsies should not be the same lesions used as RECIST target lesions, unless there are no other lesions suitable for biopsy.\n4. No prior systemic chemotherapy for recurrent or metastatic disease\n5. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment\n6. No prior exposure to immune-mediated therapy,\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including patients with SCCHN of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland)\n2. Tumor progression or recurrence within 6 months of last dose of platinum therapy in the primary treatment setting\n3. Receipt of any radiotherapy or hormonal therapy for cancer treatment within 30 days prior to first dose of study treatment\n4. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis, Crohn's disease\\], diverticulitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)","description":"Number of participants with Overall Survival (OS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"77","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup","description":"Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"10.9","spread":null},{"groupId":"OG002","value":"10.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC)","description":"Number of participants with Overall Survival (OS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Alive at 12, 18 and 24 Months in the PD-L1 TC/IC High Subgroup","description":"Percentage of patients alive","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"48.0","spread":null},{"groupId":"OG002","value":"44.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"34.7","spread":null},{"groupId":"OG002","value":"30.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"27.6","spread":null},{"groupId":"OG002","value":"26.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup","description":"Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"2.8","spread":null},{"groupId":"OG002","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) in the PD-L1 TC/IC High Subgroup","description":"Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: \\>= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"47","spread":null}]},{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup","description":"Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"12.3","spread":null},{"groupId":"OG002","value":"4.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Status in the All-comers (Full Analysis Set)","description":"Number of participants with Overall Survival (OS)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"356","spread":null},{"groupId":"OG001","value":"176","spread":null},{"groupId":"OG002","value":"171","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set)","description":"Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"9.9","spread":null},{"groupId":"OG002","value":"10.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Alive at 12, 18 and 24 Months in the All-comers (Full Analysis Set)","description":"Percentage of patients alive","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null},{"groupId":"OG001","value":"42.8","spread":null},{"groupId":"OG002","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7","spread":null},{"groupId":"OG001","value":"31.2","spread":null},{"groupId":"OG002","value":"29.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":null},{"groupId":"OG001","value":"24.7","spread":null},{"groupId":"OG002","value":"23.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) in the All-comers (Full Analysis Set)","description":"Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression).\n\nProgression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"2.8","spread":null},{"groupId":"OG002","value":"5.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) in the All-comers (Full Analysis Set)","description":"Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: \\>= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"101","spread":null}]},{"measurements":[{"groupId":"OG000","value":"323","spread":null},{"groupId":"OG001","value":"169","spread":null},{"groupId":"OG002","value":"105","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR) in the All-comers (Full Analysis Set)","description":"Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"11.9","spread":null},{"groupId":"OG002","value":"4.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":168,"n":408},"commonTop":["Fatigue","Anaemia","Rash","Diarrhoea","Nausea"]}}}